Treatment and re-treatment strategies for schistosomiasis control in different epidemiological settings: A review of 10 years' experiences

Acta Tropica

Volumn 86, Issue 2-3, 2003, Pages 243-254

  Magnussen, Pascal ^a  

^a DANISH BILHARZIASIS LABORATORY   (Denmark)

Author keywords

Morbidity control; Praziquantel treatment strategy; S. haematobium; S. japonicum; S. mansoni; Schistosomiasis

Indexed keywords

PRAZIQUANTEL;

DISEASE TREATMENT; DRUG PRESCRIBING; MORBIDITY; SCHISTOSOMIASIS;

AFRICA; ASIA; BLOOD ANALYSIS; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; EPIDEMIOLOGICAL DATA; FOLLOW UP; HEALTH PROGRAM; HEMATURIA; INFECTION PREVENTION; MICROBIOLOGICAL EXAMINATION; MORBIDITY; NONHUMAN; PARASITOLOGY; PATHOLOGY; PILOT STUDY; SCALE UP; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; TABLET; URINALYSIS; WESTERN HEMISPHERE;

SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMIASIS MANSONI;

EID: 0038740671     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(03)00045-7     Document Type: Conference Paper

References (69)

1. Abu-Elyazeed R.R., Mansour N.S., Youssef F.G., Boghdadi A.M., El Khoby T.A., Hassanein Y.A., El Gamal R.R. Seasonality as a determinant of the efficacy of praziquantel in population-based chemotherapy: lessons from the practice. J. Egypt Soc. Parasit. 28:1998;1-7.
2. Abu-Elyazeed R.R., Mansour N.S., Campbell J.R. The prevalence and intensity of Schistosoma mansoni infection among residents in two Egyptian villages, at two and 12 months post-treatment with 40 mg and 60 mg praziquantel per kg body weight at these two villages, respectively. J. Egypt Soc. Parasit. 28:1998;9-16.
3. Almeda J., Corachan M., Sousa A., Ascaso C., Carvalho J.M., Rollison D., Southgate V.R. Schistosomiasis in the Republic of São Tomé and Principe: human studies. Trans. R. Soc. Trop. Med. Hyg. 88:1994;406-409.
4. Barbosa F.S., Coimbra C.E.A. Alternative approaches in schistosomiasis control. Mem. Inst. Oswaldo Cruz, Rio de Janeiro. 87:(Suppl. IV):1992;215-220.
5. Barreto M.L. Geographical and socio-economic factors relating to the distribution of Schistosoma mansoni infection in an urban area of Northeast Brazil. Bull. WHO. 69:1991;93-102.
6. Boisier P., Serieye J., Ravaoalimalala V.E., Roux J., Esterre P. Ultrasonographical assessment of morbidity in schistosomiasis mansoni in Madagascar: a community-based study in a rural population. Trans. R. Soc. Trop. Med. Hyg. 89:1995;208-212.
7. Boisier P., Ramarokoto C.E., Ravaoalimalala V.E., Rabarijaona L., Serieye J., Roux J., Esterre P. Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. Trans. R. Soc. Trop. Med. Hyg. 92:1998;451-453.
8. Butterworth A.E., Sturrock R.F., Ouma J.H., Mbugua G.G., Fulford A.J., Kariuki H.C., Koech D. Comparison of different chemotherapy strategies against Schistosoma mansoni in Machakos District, Kenya: effects on human infection and morbidity. Parasitology. 103:1991;339-355.
9. Carabin H., Guyatt H., Engels D. A comparative analysis of the cost-effectiveness of treatment based on parasitological and symptomatic screening for Schistosoma mansoni in Burundi. Trop. Med. Int. Health. 5:2000;192-202.
10. Chan M.S., Montresor A., Savioli L., Bundy D.A.P. Planning chemotherapy based schistosomiasis control: validation of a mathematical model using data on Schistosoma haematobium from Pemba, Tanzania. Epidemiol. Infect. 123:1999;487-497.
11. Cioli D. Chemotherapy of Schistosomiasis: an update. Parasitol. Today. 14:1998;418-422.
12. Coura J.R. Control of schistosomiasis in Brazil: perspectives and proposals. Mem. Inst. Oswaldo Cruz, Rio de Janeiro. 90:1995;257-260.
13. Dandnan L., Shaoji Z., Murakami H., Zhaongdao W., Totsuya T., Xiaonan G., Guanghan H., Taihue G., Fei H. Impact of mass chemotherapy with praziquantel on schistosomiasis control in Fanhu village, People's Republic of China. Southeast Asian. J. Trop. Med. Public Health. 28:1997;274-279.
14. De Clerq F.D., Sacko M., Behnke J., Gilbert F., Vercruysse J. The relationship between Schistosoma haematobium infection and school performance and attendance in Bamako, Mali. Ann. Trop. Med. Parasitol. 92:1998;851-858.
15. Doenhoff M.J., Kimani G., Cioli D. Praziquantel and the control of Schistosomiasis. Parasitol. Today. 16:2000;364-366.
16. Doehring-Schwerdtfeger E., Abdel-Rahim I.M., Kardoff R., Kaiser C., Franke D., Schlake J., Richter J., Elsheikh M., Mohamed-Ali Q., Ehrlich J.H. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity 23 months after treatment with praziquantel. Am. J. Trop. Med. Hyg. 46:1992;409-415.
17. El Malatawy A., El Habashy A., Lechine N., Dixon H., Davis A., Mott K.E. Selective population chemotherapy among schoolchildren in Beheira Governorate: the UNICEF/Arab Republic of Egypt/WHO Schistosomiasis Control Project. Bull. WHO. 70:1992;47-56.
18. Engels D., Ndoricimpa J., Gryseels D. Schistosomiasis mansoni in Burundi: progress in its control since 1985. Bull. WHO. 71:1993;207-214.
19. Engels D., Ndoricimpa J., Nahimana B., Gryseels D. Control of Schistosoma mansoni and intestinal helminths: 8-year follow-up of an urban school program in Bujumbura, Burundi. Acta Trop. 58:1994;127-140.
20. Ernould J.C., Ba K., Sellin B. Increase of intestinal schistosomiasis after praziquantel treatment in a Schistosoma haematobium and Schistosoma mansoni mixed focus. Acta Trop. 73:1999;143-152.
21. Frenzel K., Grigull L., Odongo-Aginya E., Ndugwa C.M., Loroni-Lakwo T., Schweigmann U., Vester U., Spannbrucker N., Doehring E. Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni induced hepatosplenic lesions in northern Uganda. Am. J. Trop. Med. Hyg. 60:1999;927-931.
22. Gryseels B. Morbidity due to infection with Schistosoma mansoni: an update. Trop. Geogr. Med. 44:1992;189-200.
23. Grysseels B., Polderman A.M. The morbidity of schistosomiasis mansoni in Maniema (Zaire). Trans. R. Soc. Trop. Med. Hyg. 81:1987;202-209.
24. Grysseels B., Polderman A.M. Morbidity, due to schistosomiasis mansoni, and its control in sub-Saharan Africa. Parasitol. Today. 7:1991;244-248.
25. Gryseels B., Nkulikyinka L., Engels D. Repeated community-based chemotherapy for the control of Schistosoma mansoni: effect of screening and selective treatment on prevalences and intensities of infection. Am. J. Trop. Med. Hyg. 54:1991;509-517.
26. Hailu M., Jemaneh L., Kebede D. The use of questionnaires for the identification of communities at risk for intestinal schistosomiasis in western Gojam. Ethiop. Med. J. 33:1995;103-113.
27. Hatz C., Vennervald B.J., Nkulila T., Vounatsu P., Kombe Y., Mayombana C., Mshinda H., Tanner M. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in south-eastern Tanzania. Am. J. Trop. Med. Hyg. 59:1998;775-781.
28. Hong-Chang Y. Epidemiological features and control strategies on Schistosomiasis japonica in China. Chin. Med. J. 106:1993;563-568.
29. Hong-Chang Y. Schistosomiasis control in China. Mem. Inst. Oswaldo Cruz, Rio de Janeiro. 90:1995;297-301.
30. Hong-Chang Y., Jiagang G., Bergquist R., Tanner M., Xianyi C., Huanzeng W. The 1992-1999 World Bank Schistosomiasis Research Initiative in China: outcome and perspectives. Parasitol. Int. 49:2000;195-207.
31. King C.H., Muchiri E., Ouma J., Koech D. Chemotherapy-based control of schistosomiasis haematobia IV. Impact of repeated annual chemotherapy on prevalence and intensity of Schistosoma haematobium infection in an endemic area of Kenya. Am. J. Trop. Med. Hyg. 45:1991;498-508.
32. King C.H., Muchiri E., Ouma J. Age-targeted chemotherapy for control of urinary schistosomiasis in endemic populations. Mem. Inst. Oswaldo Cruz, Rio de Janeiro. 87:(Suppl. IV):1992;203-210.
33. Kloetzel K. Some personal views on the control of Schistosomiasis mansoni. Mem. Inst. Oswaldo Cruz, Rio de Janeiro. 87:(Suppl. IV):1992;221-226.
34. Kloetzel K., Schuster N.H. Repeated mass treatment of Schistosomiasis mansoni: experience in hyperendemic areas of Brazil. 1. Parasitological effects and morbidity. Trans. R. Soc. Trop. Med. Hyg. 81:1987;365-370.
35. Kloetzel K., Chieffi P.P., Vergetti de Siqueira J.G. Repeated mass treatment of Schistosomiasis mansoni: experience in hyperendemic areas of Brazil. 3. Techniques for assessment and surveillance. Trans. R. Soc. Trop. Med. Hyg. 84:1990;74-79.
36. Lengeler C., de Savigny D., Mshinda H., Mayombana C., Tayari S., Hatz C., Degrémont A., Tanner M. Community-based questionnaires and health statistics as tools for the cost-efficient identification of communities at risk of urinary schistosomiasis. Int. J. Epidemiol. 20:1991;796-807.
37. Lengeler C., Kilima P., Mshinda H., Morona D., Hatz C., Tanner M. Rapid, low-cost, two step method to screen for urinary schistosomiasis at the district level: the Kilosa experience. Bull. WHO. 69:1991;179-189.
38. Lengeler C., Makwala J., Ngimbi D., Utzinger J. Simple school questionnaires can map both Schistosoma mansoni and Schistosoma haematobium in the Democratic Republic of Congo. Acta Trop. 74:2000;77-87.
39. Li Y.S., Sleigh A.C., Ross A.G.P., Williams G.M., Tanner M., McManus D.P. Epidemiology of Schistosoma japonicum in China: morbidity and strategies for control in the Dongting Lake region. Int. J. Parasitol. 30:2000;273-281.
40. Li Y.S., Sleigh A.C., Ross A.G.P., Williams G.M., Tanner M., McManus D.P. Two-year impact of praziquantel treatment for Schistosoma japonicum infection in China: re-infection, subclinical disease and fibrosis marker measurements. Trans. R. Soc. Trop. Med. Hyg. 94:2000;191-197.
41. Lwambo N.J.S., Savioli L., Kisumku U.M., Alawi K.S., Bundy D.A.P. The relationship between prevalence of Schistosoma haematobium infection and different morbidity indicators during the course of a control program on Pemba Island. Trans. R. Soc. Trop. Med. Hyg. 91:1997;643-646.
42. Lwambo N.J.S., Savioli L., Kisumku U.M., Alawi K.S., Bundy D.A.P. Control of Schistosoma haematobium morbidity on Pemba Island: validity and efficiency of indirect screening tests. Bull. WHO. 75:1997;247-252.
43. Magnussen P., Muchiri E., Mungai P., Ndzovu M., Ouma J., Tosha S. A school-based approach to the control of urinary schistosomiasis and intestinal helminthes infections in children in Matuga, Kenya: impact of a 2-year chemotherapy program on prevalence and intensity of infections. Trop. Med. Int. Health. 2:1997;825-831.
44. Magnussen P., Ndawi B., Sheshe A.K., Byskov J., Christensen NØ. The impact of a school health program on the prevalence and morbidity of urinary schistosomiasis in Mwera Division, Pangani District, Tanzania. Trans. R. Soc. Trop. Med. Hyg. 95:2001;58-64.
45. Michelson M.K., Azziz A.A., Gamil F.G., Wahid A.A., Richards F.O., Juranek D.D., Habib M.A., Spencer H.C. Recent trends in the prevalence and distribution of schistosomiasis in the Nile delta region. Am. J. Trop. Med. Hyg. 49:1993;76-87.
46. Mohamed-Ali Q., Doehring-Schwerdtfeger E., Abdel-Rahim I.M., Schlake J., Kardoff R., Franke D., Kaiser C., Elsheikh M., Abdalla M., Shafer P. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity 7 months after treatment with praziquantel. Am. J. Trop. Med. Hyg. 44:1991;444-451.
47. Proietti F.A., Antunes C.M. Sensitivity, specificity and positive predictive value of selected clinical signs and symptoms associated with Schistosomiasis mansoni. Int. J. Epidemiol. 18:1989;680-683.
48. Red Urine Study Group, 1995 Identification of high risk communities for schistosomiasis in Africa. WHO TDR/SER Report Series, No 15. WHO, Geneva.
49. Ross A.G., Li Y., Booth M., Sleigh A.C., Williams G.M., McManus D.P. Five year impact of chemotherapy on morbidity attributable to Schistosoma japonicum infection in the Dongting Lake region. Trop. Med. Int. Health. 3:1998;837-841.
50. Savioli L., Hatz C., Dixon H., Kisumku U.M., Mott K.E. Control of the morbidity due to Schistosoma haematobium on Pemba Island: egg excretion and haematuria as indicators of infection. Am. J. Trop. Med. Hyg. 43:1990;289-295.
51. Savioli L., Renganathan E., Montresor A., Davis A., Behbehani K. Control of schistosomiasis - a global picture. Parasitol. Today. 13:1997;444-448.
52. Schutte C.H.J., Evans A.C., Pammenter M.D., Cooppan R.M., Pretorius S.J., Joubert P.H. Epidemiology and control of Schistosomiasis mansoni in communities living on the Cuando River floodplain of East Caprivi, Namibia. Ann. Trop. Med. Parasitol. 89:1995;631-644.
53. Spencer H.C., Ruiz-Tibén E., Mansour N.S., Cline B.L. Evaluation of UNICEF/Arab Republic of Egypt/WHO Schistosomiasis Control Project in Beheira Governorate. Am. J. Trop. Med. Hyg. 42:1990;441-448.
54. Sturrock R.F., Klumpp R.K., Ouma J., Butterworth A.E., Fulford A.J.C., Kariuki H.C., Thiong'o F.W., Koech D. Observations on the effects of different chemotherapy strategies on the transmission of Schistosoma mansoni in Machakos District, Kenya, measured by long term snail sampling and cercariometry. Parasitology. 109:1994;443-453.
55. Sukwa T.Y. A community based randomised trial of praziquantel to control schistosomiasis morbidity in school children in Zambia. Ann. Trop. Med. Parasitol. 87:1993;185-194.
56. Utzinger J., N'Goran E.K., Esse Aya C.M., Acka Adjoua C., Lohourignon K.L., Tanner M., Lengeler C. Schistosoma mansoni, intestinal parasites and perceived morbidity indicators in schoolchildren in a rural endemic area of western Côte d'Ivoire. Trop. Med. Int. Health. 3:1998;711-720.
57. Utzinger J., N'Goran E.K., N'Dri A., Lengeler C., Xiao S.H., Tanner M. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet. 355:2000;1320-1325.
58. Utzinger J., N'Goran E.K., N'Dri A., Lengeler C., Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop. Med. Int. Health. 5:2000;771-778.
59. Utzinger J., Shuhua X., N'Goran E.K., Bergquist R., Tanner M. The potential of artemether for the control of schistosomiasis. Int. J. Parasitol. 31:2001;1549-1562.
60. Vennervald J.B., Kahama A.I., Reimert C.M. Assessment of morbidity in Schistosoma haematobium infection: current methods and future tools. Acta Trop. 77:2000;81-89.
61. Wagatsuma Y., Aryeety M.E., Sack D.A., Morrow R.H., Hatz C., Kojima S. Resolution and resurgence of Schistosoma haematobium-induced pathology after community-based chemotherapy in Ghana, as detected by ultrasound. J. Infect. Dis. 179:1999;1515-1522.
62. Webbe G., El Hak S. Progress in the control of schistosomiasis in Egypt 1985-1988. Trans. R. Soc. Trop. Med. Hyg. 84:1990;394-400.
63. Wiest P.M., Wu G., Zhong S., McGarvey S.T., Yuan J., Olveda R.M., Peters P.A.S., Olds G.R. Impact of annual screening and chemotherapy with praziquantel on schistosomiasis japonica on Jishan Island, People's Republic of China. Am. J. Trop. Med. Hyg. 51:1994;162-169.
64. World Health Organization (WHO), 1985. The control of schistosomiasis. Report of a WHO Expert Committee, Geneva. World Health Organization Technical Report Serial Number 728. Geneva.
65. World Health Organization (WHO), 1993. The control of schistosomiasis. Second report of the WHO Expert Committee. World Health Organ Organization Technical Report Serial Number 830. Geneva.
66. World Health Organization (WHO), 1999a. Report of the WHO informal consultation on schistosomiasis control, 2-4 December 1998. WHO/CDS/CPC/SIP/99.2. Geneva.
67. World Health Organization (WHO), 1999b. Report of the WHO informal consultation on monitoring of drug efficacy in the control of schistosomiasis and intestinal nematodes, 8-10 July 1998. WHO/CDS/CPC/SIP/99.1. Geneva.
68. World Health Organization (WHO), 2001. Report of the WHO informal consultation on schistosomiasis in low transmission areas: control strategies and criteria for elimination, 10-13 April 2000. WHO/CDS/CPE/SIP/2001.1. Geneva.
69. Zhou H., Ross A.G.P., Hartel G.F., Sleigh A.C., Williams G.M., McManus D.P., Luo X.S., He Y., Li Y.S. Diagnosis of schistosomiasis japonica in Chinese schoolchildren by administration of a questionnaire. Trans. R. Soc. Trop. Med. Hyg. 92:1998;245-250.